Lantern Cleared for Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas

 

• This is the second IND Clearance over the last 100 days for drug candidates that are being developed using guidance from Lantern’s AI Platform, RADR^®.
• LP-284 is the second of Lantern’s synthetic-lethal franchise of molecules that have shown to be synthetically lethal in DNA damage repair deficient cancers and are entering into first-in-human clinical trials.
• Lantern estimates that LP-284 can have the potential to improve outcomes for 40,000 to 80,000 patients with blood cancers annually, with a global annual market potential of $4 Billion USD.

https://www.biospace.com/article/releases/lantern-pharma-receives-ind-clearance-from-fda-enabling-phase-1-initiation-for-drug-candidate-lp-284-in-non-hodgkin-s-lymphomas/